Cargando…

Tumor Immune Microenvironment in Lymphoma: Focus on Epigenetics

SIMPLE SUMMARY: Lymphoma and other cancers have been studied by mainly focusing on malignant cells. However, research findings about the role of the tumor microenvironment in the progression and immunosuppression of cancer, particularly in lymphomas, have increased considerably in recent years, allo...

Descripción completa

Detalles Bibliográficos
Autores principales: García-Domínguez, Daniel J., Hontecillas-Prieto, Lourdes, Palazón-Carrión, Natalia, Jiménez-Cortegana, Carlos, Sánchez-Margalet, Víctor, de la Cruz-Merino, Luis
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8946119/
https://www.ncbi.nlm.nih.gov/pubmed/35326620
http://dx.doi.org/10.3390/cancers14061469
_version_ 1784674118577160192
author García-Domínguez, Daniel J.
Hontecillas-Prieto, Lourdes
Palazón-Carrión, Natalia
Jiménez-Cortegana, Carlos
Sánchez-Margalet, Víctor
de la Cruz-Merino, Luis
author_facet García-Domínguez, Daniel J.
Hontecillas-Prieto, Lourdes
Palazón-Carrión, Natalia
Jiménez-Cortegana, Carlos
Sánchez-Margalet, Víctor
de la Cruz-Merino, Luis
author_sort García-Domínguez, Daniel J.
collection PubMed
description SIMPLE SUMMARY: Lymphoma and other cancers have been studied by mainly focusing on malignant cells. However, research findings about the role of the tumor microenvironment in the progression and immunosuppression of cancer, particularly in lymphomas, have increased considerably in recent years, allowing for a better understanding of the disease. Consequently, epigenetic mechanisms that are implicated in the interplay between tumor cells and the different components around them, promoting the survival and progression of the tumor, have been described. This review tries to summarize the complex interplay between lymphoma tumor cells and immune cells as well as the epigenetic alterations that result from this cross-talk, aiming at contributing towards underlining the value of epigenetic modifications as new biomarkers and the use of epigenetic drugs as an interesting therapeutic option. ABSTRACT: Lymphoma is a neoplasm arising from B or T lymphocytes or natural killer cells characterized by clonal lymphoproliferation. This tumor comprises a diverse and heterogeneous group of malignancies with distinct clinical, histopathological, and molecular characteristics. Despite advances in lymphoma treatment, clinical outcomes of patients with relapsed or refractory disease remain poor. Thus, a deeper understanding of molecular pathogenesis and tumor progression of lymphoma is required. Epigenetic alterations contribute to cancer initiation, progression, and drug resistance. In fact, over the past decade, dysregulation of epigenetic mechanisms has been identified in lymphomas, and the knowledge of the epigenetic aberrations has led to the emergence of the promising epigenetic therapy field in lymphoma tumors. However, epigenetic aberrations in lymphoma not only have been found in tumor cells, but also in cells from the tumor microenvironment, such as immune cells. Whereas the epigenetic dysregulation in lymphoma cells is being intensively investigated, there are limited studies regarding the epigenetic mechanisms that affect the functions of immune cells from the tumor microenvironment in lymphoma. Therefore, this review tries to provide a general overview of epigenetic alterations that affect both lymphoma cells and infiltrating immune cells within the tumor, as well as the epigenetic cross-talk between them.
format Online
Article
Text
id pubmed-8946119
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-89461192022-03-25 Tumor Immune Microenvironment in Lymphoma: Focus on Epigenetics García-Domínguez, Daniel J. Hontecillas-Prieto, Lourdes Palazón-Carrión, Natalia Jiménez-Cortegana, Carlos Sánchez-Margalet, Víctor de la Cruz-Merino, Luis Cancers (Basel) Review SIMPLE SUMMARY: Lymphoma and other cancers have been studied by mainly focusing on malignant cells. However, research findings about the role of the tumor microenvironment in the progression and immunosuppression of cancer, particularly in lymphomas, have increased considerably in recent years, allowing for a better understanding of the disease. Consequently, epigenetic mechanisms that are implicated in the interplay between tumor cells and the different components around them, promoting the survival and progression of the tumor, have been described. This review tries to summarize the complex interplay between lymphoma tumor cells and immune cells as well as the epigenetic alterations that result from this cross-talk, aiming at contributing towards underlining the value of epigenetic modifications as new biomarkers and the use of epigenetic drugs as an interesting therapeutic option. ABSTRACT: Lymphoma is a neoplasm arising from B or T lymphocytes or natural killer cells characterized by clonal lymphoproliferation. This tumor comprises a diverse and heterogeneous group of malignancies with distinct clinical, histopathological, and molecular characteristics. Despite advances in lymphoma treatment, clinical outcomes of patients with relapsed or refractory disease remain poor. Thus, a deeper understanding of molecular pathogenesis and tumor progression of lymphoma is required. Epigenetic alterations contribute to cancer initiation, progression, and drug resistance. In fact, over the past decade, dysregulation of epigenetic mechanisms has been identified in lymphomas, and the knowledge of the epigenetic aberrations has led to the emergence of the promising epigenetic therapy field in lymphoma tumors. However, epigenetic aberrations in lymphoma not only have been found in tumor cells, but also in cells from the tumor microenvironment, such as immune cells. Whereas the epigenetic dysregulation in lymphoma cells is being intensively investigated, there are limited studies regarding the epigenetic mechanisms that affect the functions of immune cells from the tumor microenvironment in lymphoma. Therefore, this review tries to provide a general overview of epigenetic alterations that affect both lymphoma cells and infiltrating immune cells within the tumor, as well as the epigenetic cross-talk between them. MDPI 2022-03-13 /pmc/articles/PMC8946119/ /pubmed/35326620 http://dx.doi.org/10.3390/cancers14061469 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
García-Domínguez, Daniel J.
Hontecillas-Prieto, Lourdes
Palazón-Carrión, Natalia
Jiménez-Cortegana, Carlos
Sánchez-Margalet, Víctor
de la Cruz-Merino, Luis
Tumor Immune Microenvironment in Lymphoma: Focus on Epigenetics
title Tumor Immune Microenvironment in Lymphoma: Focus on Epigenetics
title_full Tumor Immune Microenvironment in Lymphoma: Focus on Epigenetics
title_fullStr Tumor Immune Microenvironment in Lymphoma: Focus on Epigenetics
title_full_unstemmed Tumor Immune Microenvironment in Lymphoma: Focus on Epigenetics
title_short Tumor Immune Microenvironment in Lymphoma: Focus on Epigenetics
title_sort tumor immune microenvironment in lymphoma: focus on epigenetics
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8946119/
https://www.ncbi.nlm.nih.gov/pubmed/35326620
http://dx.doi.org/10.3390/cancers14061469
work_keys_str_mv AT garciadominguezdanielj tumorimmunemicroenvironmentinlymphomafocusonepigenetics
AT hontecillasprietolourdes tumorimmunemicroenvironmentinlymphomafocusonepigenetics
AT palazoncarrionnatalia tumorimmunemicroenvironmentinlymphomafocusonepigenetics
AT jimenezcorteganacarlos tumorimmunemicroenvironmentinlymphomafocusonepigenetics
AT sanchezmargaletvictor tumorimmunemicroenvironmentinlymphomafocusonepigenetics
AT delacruzmerinoluis tumorimmunemicroenvironmentinlymphomafocusonepigenetics